An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn’s disease previously included in the loss of RESponse to Ustekinumab treated by dose Escalation study (REScUE-OLE) - RESCUE-OLE

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2021
This article has no abstract
Epistemonikos ID: b943a80ab8ae78e36c21dcbd856fc8c4b71b52a9
First added on: Apr 17, 2025